The global humanized mouse model market size was USD 108.9 Million in 2020 and is expected to register a CAGR of 10.2% during the forecast period. Increasing research activities involving humanized mice models, growth in the biopharmaceutical sector, increasing progress in drug research and development, and rising demand for personalized medicine are key factors expected to drive market revenue growth over the forecast period. In addition, rapid technological advancements, rapid development in oncology research, and increasing private and public funding are factors expected to further contribute to revenue growth of the market going ahead.
Humanized mouse model is a mouse that has been xenotransplanted with human cells or are engineered to express human genes so that can be extensively used in elucidating and understanding physiology and pathologies concerning humans. Humanized mice are chiefly used as small animal models in biomedical research for developing human therapeutics. These mice provide various advantages to researchers owing to their small size, short-term reproductive cycle, easy handling, and genomic similarity to humans. Moreover, these mice can also be easily genetically modified. Humanized mouse models have been developed with a purpose to overcome several limitations of traditional mice models such as dissimilarity in immune systems between humans and mice models. Humanized mice models are critical in numerous preclinical researches as these can mimic human pathological conditions and are widely used to assess the efficacy of immunotherapy approaches. Humanized mice models are used in research studies of infectious diseases, transplantation, regenerative medicine, and cancer biology. Humanized mouse models also played a major role in development of vaccines and antibody-based therapies against COVID-19 illness. Scientists developed a triple immunodeficient humanized mouse model that engrafts CD34+ cord blood and supports hematopoiesis of human immune cells that express ACE2, a receptor that the coronavirus exploits to enter the human cells. This model and other models, which have been developed since the COVID-19 outbreak are expected to provide a better understanding of SARS-CoV-2 infection, efficacy of anti-virus therapies, and contribute to development of efficient drugs for treatment and prevention of this disease.
Request a Sample@ https://qyresearchmedical.com/sample/118919
Rapid technological advancements and the advent of genetic engineering of mouse genome have contributed to significant revenue growth of the market over the recent past and this trend is expected to continue going ahead. However, stringent regulations and laws regarding ethical use of animals in research and increasing use of humanized rat models are expected to hamper market growth over the forecast period.
Market Dynamics
Driver: Increasing need for personalized medicine and advancement in gene editing tools are key revenue growth driving factors
Precision or personalized medicine involves development of tailored medications or therapeutic approaches to develop target treatment by address individual complexity and genetic variations. These medicines are developed through the use of mice models, particularly immunodeficient mouse model to express human-specific pathologies. This enables researchers to develop targeted therapeutic approaches including drugs and gene therapies to determine most suitable treatment. This is expected to drive revenue growth of the market over the forecast period. The advent of advanced gene editing tools such as CRISPR/Cas9 technology have accelerated the development of mutant and genetically engineered mice to study characteristics of various diseases. This is also expected to contribute to revenue growth of the market going ahead.
Restraint: High costs associated with development of humanized mice models expected to restrain market growth
Humanized mouse models are developed by grafting human tissues, genes, and cells into immunodeficient mice. These experiments incur huge expenses in production and maintenance of these models. This has limited the adoption of humanized mouse models across the globe and is expected to restrain market growth to a certain extent over the forecast period. In addition, stringent regulations regarding use of animals in experiments and preclinical studies is also expected to hamper market growth to a significant extent going ahead.
Type Outlook:
Based on type, the global humanized mouse model market has been segmented into genetic and cell-based. Cell-based has been further segmented into CD34, PMBC, and BLT humanized models. Genetic humanized mouse model segment is expected to account for largest revenue share over the forecast period attributable to extensive use of genetic humanized mouse models in experimental analysis of compounds including their safety and efficacy. Increasing use of these mouse model in assessment of drug metabolism and disposition to accelerate drug research and development is also expected to contribute to revenue growth of this segment over the forecast period.
Application Outlook:
Based on application, the global humanized mouse model market has been segmented into neuroscience, hematopoiesis, oncology, toxicology, infectious diseases, and others. Oncology segment is expected to register rapid revenue CAGR over the forecast period owing to increasing prevalence of cancer, growing cancer research and development activities, and rising need to meet the unmet clinical demands. Humanized mice models are considered to be more realistic models to study tumor biology as compared to cultured cancer cells and this is also expected to contribute significantly to revenue growth of the market over the forecast period.
End-use Outlook:
Based on end-use, the global humanized mouse model market has been segmented into pharmaceutical & biotechnology companies, Contract Research Organizations (CROs), and academic & research institutions. The contract research organizations segment is expected to register considerable revenue growth over the forecast period. Growth can be attributed to increasing number of pharmaceutical and biotechnology companies outsourcing their drug discovery and development activities and preclinical studies to CROs. In addition, rapidly rising network of CROs across the globe, increasing expenditure by CROs on clinical studies, and technological advancements are expected to further boost revenue growth of this segment during the forecast period.
Regional Outlook:
Based on regional analysis, North America is expected to account for largest share in the global market in terms of revenue over the forecast period. Growth can be attributed to increasing pharmaceutical and biotechnology research in the United States, growing biopharmaceutical sector, rising demand and production of monoclonal antibodies, and increasing advancement in protein therapeutics. Growing number of preclinical and clinical activities by CROs, rapid progress in stem cell research, and increasing support from government are also expected to drive revenue growth of the market in the region.
Asia Pacific is expected to register robust revenue CAGR during the forecast period owing to rapid growth of biomedical sector, advancement in translational research, and increasing demand for precision medicine in in India, China, Japan, and other APAC countries. China is expected to account for largest revenue share in the APAC market owing to increasing animal research, mandatory animal testing for pharmaceutical drugs and cosmetics, growing biomedical sector, and rapid rise in strategic alliances between research institutes in China and international institutes and companies. In addition, availability of massive target patient pool, low cost of clinical trials, and lenient regulatory approvals are also expected to drive revenue growth of the market in the region.
Competitive Landscape:
Competitive landscape of the global humanized mouse model market is fragmented and comprises numerous players on global and regional level. Key players are focused on research and development activities, technological advancement, and strategic alliances such as mergers and acquisitions, collaborations, partnerships, and joint ventures to expand their product portfolio and gain a robust footing in the global market. Major companies operating in the market include The Jackson Laboratory, Taconic Biosciences, Inc., Horizon Discovery Group Plc, genOway, S.A., Charles River Laboratories, Harbour Antibodies BV, Hera BioLabs, Vitalstar Biotechnology Co., Ltd., inGenious Targeting Laboratory, AXENIS S.A.S, Crown Bioscience, Inc., Transgenic, Inc., and Champions Oncology, Inc., among others.
Some key developments in the market:
- In February 2020, Taconic Biosciences, which is a leading provider of drug discovery animal model solutions, announced expansion of its humanized mouse model production in Europe. Local production of these humanized mouse models will enabled European researchers to have easy and timely access to this crucial immune-oncology research asset.
- In April 2021, AbCellera and Gilead Sciences announced an expansion of their already established collaboration agreement to include multi-year, multi-target antibody discovery partnership and access to the former’s humanized mouse technology, Trianni Mouse. Under this new agreement, AbCellera, which is a Canada-based biotechnology company, will develop antibody panels for nearly 8 novel targets for multiple indications which will be selected by Gilead.
- In April 2021, Inotiv, Inc., which is a U.S.-based prominent provider of nonclinical and analytical contract research facilities, announced a strategic partnership with Japanese biopharmaceutical company, PhoenixBio Co. Ltd. to offer research services in the former’s U.S. labs using proprietary PXB-mouse research model of PhoenixBio. The mouse model is a liver-humanized chimeric model which is extensively used for drug discovery and early development.
Segments Covered in the Report:
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of the market trends in each of the sub-segments from 2019 to 2030. For this study, Reports and Data has segmented the global humanized mouse model market based on type, application, end-use, and region:
Humanized Mouse Model Market Report Scope
Segments covered By Type Outlook, Application Outlook, End-use Outlook, Regional Outlook
By Type Outlook
Genetic
Cell-based
CD34 Humanized Mouse Models
PBMC Humanized Mouse Models
BLT Humanized Mouse Models
By Application Outlook
Oncology
Immunology
Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Other Applications
By End-use Outlook
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutions
Regional scope
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118919/1500
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/